×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal
WSJ
Gilead is paying $32.50 a share in cash for CymaBay, a roughly 27% premium to Friday's closing price of $25.69 and well above CymaBay's prior...
3 months ago
CymaBay Therapeutics to Present at Upcoming Conferences
Yahoo News UK
CymaBay Therapeutics, Inc. , today announced that senior management will present an overview of the company at the following upcoming...
2 days ago
Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
STAT
CymaBay's drug is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women.
3 months ago
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn
Pharmaceutical Technology
Gilead Sciences has concluded the acquisition of CymaBay Therapeutics in a transaction valued at approximately $4.3bn.
1 month ago
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
PR Newswire
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis. CymaBay...
5 months ago
Gilead to Buy CymaBay, Lead Liver Disease Asset Seladelpar for $4.3B
BioSpace
Gilead Sciences announced Monday it will purchase CymaBay Therapeutics and its investigational treatment seladelpar for primary biliary...
3 months ago
Gilead to buy CymaBay for $4.3 bln in bets on liver disease treatment
Reuters
Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with...
3 months ago
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Investopedia
Gilead Sciences is buying CymaBay Therapeutics for $4.3 billion, giving Gilead access to CymaBay's lead treatment for liver disease.
3 months ago
Gilead Buying Liver Disease Drugmaker CymaBay For $4.3B
Law360
Gilead Sciences Inc. said Monday that it has agreed to purchase liver disease-focused clinical-stage biopharmaceutical company CymaBay...
3 months ago
CymaBay Investor Alleges Gilead Buyout Filing Omits Conflicts
Bloomberg Law News
CymaBay Therapeutics Inc. and its directors left key details out of a solicitation statement for Gilead Sciences Inc.'s proposed $4.3...
2 months ago